abstract |
Provided in the present invention are an IL-2 mutant protein, a fusion protein or conjugate containing the IL-2 mutant protein, and a pharmaceutical composition containing the IL-2 mutant protein, fusion protein or conjugate. Compared with wild-type IL-2 protein, the IL-2 mutant protein of the present invention eliminates or reduces the affinity for a high-affinity IL-2 receptor and substantially retains the affinity for a medium-affinity IL-2 receptor. |